| 000 | 01862 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516180814.0 | ||
| 264 | 0 | _c20150109 | |
| 008 | 201501s 0 0 eng d | ||
| 022 | _a1773-0449 | ||
| 024 | 7 |
_a10.1016/j.mycmed.2013.10.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoux, C | |
| 245 | 0 | 0 |
_aProstatic and renal aspergillosis due to Aspergillus fumigatus in a patient receiving alemtuzumab for chronic lymphocytic leukaemia. _h[electronic resource] |
| 260 |
_bJournal de mycologie medicale _cDec 2013 |
||
| 300 |
_a270-3 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_aAbscess _xetiology |
| 650 | 0 | 4 |
_aAcyclovir _xanalogs & derivatives |
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
| 650 | 0 | 4 | _aAntibiotic Prophylaxis |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAntifungal Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aAspergillosis _xetiology |
| 650 | 0 | 4 |
_aAspergillus fumigatus _xisolation & purification |
| 650 | 0 | 4 | _aDrug Resistance, Fungal |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunocompromised Host |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNephritis _xetiology |
| 650 | 0 | 4 |
_aProstatitis _xetiology |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aValacyclovir |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aVoriconazole _xtherapeutic use |
| 700 | 1 | _aThyss, A | |
| 700 | 1 | _aGari-Toussaint, M | |
| 773 | 0 |
_tJournal de mycologie medicale _gvol. 23 _gno. 4 _gp. 270-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.mycmed.2013.10.001 _zAvailable from publisher's website |
| 999 |
_c23246902 _d23246902 |
||